Figure 2.
Auto-HCT vs CAR-T in patients with DLBCL in PR (patients with ≤2 prior lines of treatment). (A) Progression-free survival. (B) Nonrelapse mortality. (C) Progression/relapse. (D) Overall survival.

Auto-HCT vs CAR-T in patients with DLBCL in PR (patients with ≤2 prior lines of treatment). (A) Progression-free survival. (B) Nonrelapse mortality. (C) Progression/relapse. (D) Overall survival.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal